Clinical Trial Update: Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod

View source ↗

Summary

A completed clinical trial evaluated disease control when switching RRMS patients from natalizumab to fingolimod.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• GILENYA (FINGOLIMOD HCL)
• Tysabri (Natalizumab)

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: Relapsing Remitting Multiple Sclerosis | Status: COMPLETED